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Abstract
Background: Aortic calcification is a major risk factor for death from cardiovascular disease. We investigated the
relationship between mortality and the composite markers of number, size, morphology and distribution of
calcified plaques in the lumbar aorta.
Methods: 308 postmenopausal women aged 48-76 were followed for 8.3 ± 0.3 years, with deaths related to
cardiovascular disease, cancer, or other causes being recorded. From lumbar X-rays at baseline the number (NCD),
size, morphology and distribution of aortic calcification lesions were scored and combined into one Morphological
Atherosclerotic Calcification Distribution (MACD) index. The hazard ratio for mortality was calculated for the MACD
and for three other commonly used predictors: the EU SCORE card, the Framingham Coronary Heart Disease Risk
Score (Framingham score), and the gold standard Aortic Calcification Severity score (AC24) developed from the
Framingham Heart Study cohorts.
Results: All four scoring systems showed increasing age, smoking, and raised triglyceride levels were the main
predictors of mortality after adjustment for all other metabolic and physical parameters. The SCORE card and the
Framingham score resulted in a mortality hazard ratio increase per standard deviation (HR/SD) of 1.8 (1.51-2.13) and
2.6 (1.87-3.71), respectively. Of the morphological x-ray based measures, NCD revealed a HR/SD >2 adjusted for
SCORE/Framingham. The MACD index scoring the distribution, size, morphology and number of lesions revealed
the best predictive power for identification of patients at risk of mortality, with a hazard ratio of 15.6 (p < 0.001) for
the 10% at greatest risk of death.
Conclusions: This study shows that it is not just the extent of aortic calcification that predicts risk of mortality, but
also the distribution, shape and size of calcified lesions. The MACD index may provide a more sensitive predictor of
mortality from aortic calcification than the commonly used AC24 and SCORE/Framingham point card systems.
Background
Cardiovascular diseases (CVD) remain the most com-
mon cause of death in the developed world, even though
vast epidemiological and interventional studies have
demonstrated significant declines in CVD prevalence
with adherence to a healthy lifestyle, and the identifica-
tion and management of risk factors [1] . Since two
thirds of women who die suddenly from CVD have no
previously recognized symptoms [2], it is essential to
find effective indicators of cardiovascular risk that may
prompt timely intervention.
Biomarkers and biochemical markers are receiving
increased attention for their potential prognostic value,
and for identification of those patients in most need of
intervention [3]. An extensive list of more than 200
potential CVD risk factors has been compiled [4] and
multivariate analysis models, such as the EU SCORE
card [5] and the Framingham Coronary Heart Disease
Risk Score (Framingham score) [6], have been developed
to estimate risk of CVD death. However, more
* Correspondence: madsn@diku.dk
1Department of Computer Science, University of Copenhagen, Copenhagen,
Denmark
Full list of author information is available at the end of the article
Nielsen et al. BMC Cardiovascular Disorders 2010, 10:56
http://www.biomedcentral.com/1471-2261/10/56
© 2010 Nielsen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.information may be provided by in-depth analysis of
already-established risk factors.
Recently, several interesting findings have been
reported on abdominal aortic calcifications as a CVD
risk factor: i) Premature parental CVD has been asso-
ciated with abdominal aortic calcification [7]. ii) Abdom-
inal aortic calcium levels were significantly related to
coronary calcium levels independent of the usual risk
factors [8,9]. iii) In type II diabetes patients, abdominal
aortic calcification was shown to constitute an indepen-
dent risk factor of clinical vascular disease [10]. iv) An
increased total-to-high density lipoprotein (HDL) cho-
lesterol ratio increased the risk of presence of aortic cal-
cification [11]. v) Lumbar aortic calcifications in bone
densitometer images have been shown to constitute an
independent risk factor of CVD [12]. Hence, abdominal
aortic calcification is an important risk factor for CVD.
Further investigations have indicated that it is rather
the number of active lipid-laden remodelling, growing,
plaques, rather than the total burden of calcified pla-
ques, including stable plaques, that is related to cardio-
vascular death [13]. Also the number, distribution and
size of calcified plaques have been shown to relate to
mortality[14]. As the Aortic Calcification Severity score
(AC24) assesses, in terms of lesions, only the extent of
calcification in the aorta, we developed a broader Mor-
phological Atherosclerotic Calcification Distribution
(MACD) index specifically to score the number, length,
width, shape, and distribution of abdominal aortic calci-
fications (AAC) found in lumbar X-rays of postmeno-
pausal women. This index was created to further
understand the composition of the plaque burden in
relation to cardiovascular death. Low dose computed
tomography might have been used to evaluate coronary
calcifications for screening purposes [15], however its
cost is a limiting factor.
We evaluated whether each risk included in the com-
posite MACD marker persisted after correction for gen-
eralized risk assessments used in the SCORE card [16],
the Framingham score [17] or individual risk factors,
such as smoking, cholesterol or triglycerides levels.
Methods
Subjects
In 1992-93, 686 postmenopausal women living in the
Copenhagen area in Denmark were recruited via a
household postal survey to participate in a study addres-
sing the role of a number of metabolic risk factors in
the pathogenesis of CVD and osteoporosis [18].
Follow-up was performed after 8.5 years and informa-
tion about all 95 individuals who died in the observation
period was obtained from the Central Registry of the
Danish Ministry of Health. All participants gave
informed consent to participate in 1992-93 and the
study was carried out according to the Helsinki Declara-
tion II and the European Standards of Good Clinical
Practice. Local ethics committees approved the study
protocol.
Markers
At baseline, information was collected on demographics
and known risk parameters such as age, weight, height,
body mass index (BMI), waist and hip circumferences,
systolic and diastolic blood pressure (BP), treated hyper-
tension, treated diabetes, smoking, regular alcohol and
daily coffee consumption, and weekly fitness activity.
Using a blood analyzer (Cobas Mira Plus, Roche Diag-
nostics Systems, Hoffman-La Roche, Basel, Switzerland),
fasting glucose levels and lipid profiles, consisting of
total cholesterol, triglycerides, LDL-cholesterol (LDL-C),
HDL-cholesterol (HDL-C), and apolipoproteins (ApoA
and ApoB), were obtained.
On basis of these measurements, the composite risk
SCORE card [19] and Framingham score [20] were both
calculated based on the gender, age, systolic blood pres-
sure, total cholesterol, and smoking status; and the Fra-
mingham score also based on HDL-C.
Lateral X-rays of the lumbar aorta (L1-L4 vertebrae)
were taken at baseline and at follow-up. The images
were digitized using a Vidar DosimetryPro Advantage
scanner providing an image resolution of 9651 times
4008 pixels on a 12-bit grey scale using a pixel size of
44.6 μm
2. Trained, blinded radiologists annotated the
digitized images on a Sectra radiological reading unit
using annotation software developed in Matlab (Math-
works, MA, USA) (Figure 1). The radiologists were
instructed to annotate the 6 points used for vertebral
height measurements on L1 - L4 [21], to delineate the
aorta, and finally to outline every individual calcified
deposit visible in the lumbar aorta and note their possi-
ble association to the anterior and/or posterior wall.
The software enabled digital zooming and editing [22].
The inter- and intra- observer variability was tested by
Figure 1 Calcification Annotations. Lateral lumbar X-ray with
calcifications in the lower region without (a) and with (b)
computer-mediated annotations performed by radiologist.
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selected images, 3 times each.
Geometric data relating to the calcified deposits in the
L1-L4 region was quantified as follows:
Area %
The percentage of the projected aorta lumen area occu-
pied by calcified deposits.
Thickness %
The average thickness of the calcified deposits along the
aorta wall, expressed as a percentage of the aorta width.
Wall %
The percentage of the aorta wall covered by calcified
deposits.
Length %
The percentage of the length of the aorta in which a cal-
cified deposit was present, in any position (anterior, pos-
terior or internal).
Number of Calcified Deposits (NCD)
The number of distinct calcified deposits.
Simulated Plaque Area
As x-rays only capture the calcified core and not the
biological extent of atherosclerotic lesions, we imple-
mented a statistically validated method[14], in which the
atherosclerotic plaque size was estimated from the area
and form of the observed calcified lesion, and the result-
ing area percentage was recorded. The estimation was
done using a grass-fire equation based on a morphologi-
cal dilation [23] with a circular structuring element of
radius 200 pixels corresponding to 8.9 mm. The biologi-
cal extent of atherosclerotic lesions around an elongated
calcified lesion was estimated to be larger than the bio-
logical extent of atherosclerotic lesions around a circular
calcification of similar size. Thus, equal areas of calcifi-
cation but of different shapes were given different scores
(see Figure 2).
The relationship between these individual markers
(number of plaques, their thickness, and the percentage
of the aorta area, wall, and length in which plaques were
detected, as well as the simulated extent of plaques) and
CVD mortality in this cohort has already been demon-
strated[14].
Calculation of the MACD Index
Two novel composite markers were created:
1. Morphological Atherosclerotic Distribution (MAD) factor
The Simulated Plaque Area divided by the Area esti-
mated that portion of the biological atherosclerotic pro-
cess which is not detected by x-rays.
2. Morphological Atherosclerotic Calcification Distribution
(MACD) index
The NCD multiplied by the MAD factor. Biologically
that can be understood as the number of plaques multi-
plied by the disease potential score described by the
MAD factor.
Statistical analysis
Patients were stratified into survivors and deceased. The
latter were sub-stratified into CVD-related, cancer-
related and other-cause deaths. Since cancer and CVD
have many risk factors in common, an additional group
containing all cancer or CVD deaths was created to
increase numbers and improve statistical significance.
Prognostic power and additional prognostic power
To test the prognostic power, metabolic and physical
parameters and AAC markers were used in separate
Cox-regression models with the time of death as the
outcome variable while right-censoring survivors. Signif-
icance was tested as the model weight being significantly
different from zero. To test if one marker carried addi-
tional prognostic power compared to the remaining
markers, a model including all elementary metabolic/
physical parameters was sequentially stripped for the
insignificant markers until significance persisted for all
markers. To test if an AAC marker carried prognostic
power in addition to the other AAC markers and/or
metabolic/physical markers, each marker was compared
in combined stripped models. Separate models for CVD,
CVD/cancer and all-cause death were created.
Predictive power in high risk groups
As CVD and CVD/cancer death rates were 6.5% and
15.2% respectively, a 10% percentile cut-off was used to
separate subjects at high risk, from those (90%) at nor-
mal risk. Hazard ratios were computed, adjusted for the
influence of other risk parameters by combining all
other risk factors into Cox-regression models. Their
differences were assessed by Wald tests.
Identification of patients at risk
Finally, the power of individual markers to identify
patients at risk was quantified by Receiver-Operator
Characteristics (ROC) curve analysis using DeLong’s test
of significantly different areas under the curve (AUC)
[24]. Pairs of markers, derived from pair-wise Cox
regression models, were also tested to see whether iden-
tification of risk improved.
Data were expressed as mean ± standard deviation
unless otherwise indicated. Variables based on concen-
trations, areas, or counts (including simulated area,
MAD factor, and MACD index) were logged to
approach normality before inclusion into models. Rela-
tive risks were computed as the per-standard-deviation
increase. All tests were two-sided and considered signifi-
cant when p < 0.05.
Results
Of the 686 postmenopausal women enrolled in the ori-
ginal study in 1992-93, 95 died prior to follow-up with
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Page 3 of 1052 (55%) of them having baseline x-ray examinations in
which the full lumbar (L1-L4) aorta was visible on a sin-
gle radiograph. Of these 52 deaths, 20 (38%) were due to
CVD, 27 (52%) to cancer and 5 (10%) to other causes.
A n o t h e r1 2 9w o m e nh a dr e l o c a t e df r o mt h eC o p e n h a -
gen area or did not want to participate in the follow-up
study and provided no clinical data for it.
Of the 462 women completing the follow-up visit,
lumbar aorta from 256 (55%) were visible on a single
radiograph (Figure 3). This compares with the aorta visi-
bility percentage reported in earlier studies [25] . There-
fore in total, 308 (52 plus 256) women were included in
the current analysis. Baseline demographics and risk
parameters showed no difference between the discontin-
ued women and those completing the study.
Observer reproducibility, assessed by three radiologists
scoring the same 16 x-rays, three times each, resulted in
both inter- and intra- observer specificity of 0.99 and an
area overlap dice score of 56% and 60% respectively,
showing good reproducibility[26]. These annotations
were used to compute the AC24 that ranges from 0 to
24 based on the length of the vertebral sections affected
by calcified deposits[27].
Death prediction by metabolic and physical markers
Most of the physical and metabolic markers provided
prognostic separation of the groups of survivors and
deceased as depicted in Table 1. In a combined model
including all physical/metabolic parameters only age,
smoking, and triglyceride level persisted after elimina-
tion of insignificant contributions. All three parameters
were positively associated with death. These were com-
bined into one parameter denoted “combined meta-
bolic/physical parameter” (HR per SD = 2.94 (2.18-3.95),
p < 0.001) for further analysis.
Death predicted by AAC markers
All imaging-based AAC markers showed higher values
in the CVD, cancer, and combined CVD/cancer groups
than in the survivor group (Table 2) and independently
and significantly predicted death in the CVD and com-
bined CVD/cancer groups (Table 3, column 2).
Additional information from AAC markers
This significance persisted for Simulated Area, NCD,
MAD factor, and MACD also when adjusted for the
combined metabolic/physical parameter, EU SCORE, or
Framingham score. AC24, Wall%, and Length% all
maintained a significant prediction under adjustment in
the CVD/Cancer group, but did not have sufficient sta-
tistical power in the smaller CVD group (Table 3).
In a combined elimination model using all elementary
calcification markers, only the number of calcified
deposits (NCD0 (positive association to death) and Area
% (negative association to death) persisted in the CVD
group (HR/SD = 4.10 (2.68-6.29), p < 0.001) and the
CVD/Cancer group (HR/SD = 2.80 (2.16-3.63), p <
0.001. In similar models adjusting for the combined
Figure 2 For a given amount of calcified tissue, one can see schematically how the AC24, the NCD and the MACD can be influenced
differently by variations in calcification morphology and distribution.
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Page 4 of 10Figure 3 Of 557 postmenopausal women who completed an 8.5 year follow-up study, 55% of those alive at follow-up and 55% of
those who were deceased had useful X-rays with the full abdominal aorta visible in a single x-ray. Thus, the study population included
in this analysis consisted of a total of 308 women: 256 survivors and 52 deceased.
Table 1 Population characteristics and hazard ratio of all-cause death (HR) per standard deviation of metabolic/
physical markers and their 95% confidence interval based on a Cox regression model
Physical/Systemic markers Population
(n = 308)
Survivors
(n = 256)
Deceased (All cause)
(n = 52)
HR per SD [95% CI]
Alone
HR per SD [95% CI]
Combined
Age (years) 60.3 ± 7.5 59.3 ± 7.1 65.6 ± 7.0 2.25*** (1.67-3.03) 2.41*** (1.75-3.31)
Waist (cm) 80.7 ± 10.9 80.2 ± 9.9 83.1 ± 12.4 1.29* (1.01-1.65) -
Waist-to-hip ratio 0.80 ± 0.08 0.80 ± 0.08 0.83 ± 0.10 1.37** (1.12-1.67) -
BMI (kg/m2) 24.7 ± 3.9 24.7 ± 3.8 25.1 ± 4.6 - -
Smoking (%) 37 33 58 1.37** (1.08-1.73) 1.50** (1.17-1.94)
Systolic BP (mm Hg) 127 ± 21 125 ± 20 136 ± 26 1.53*** (1.20-1.94) -
Diastolic BP (mm Hg) 77 ± 10 76 ± 10 77 ± 11 - -
Hypertension (%) 16 15 17 - -
Glucose (mmol/L) 5.44 ± 1.27 5.37 ± 0.99 5.79 ± 2.17 1.23* (1.03-1.46) -
Total cholesterol (mmol/L) 6.44 ± 1.19 6.36 ± 1.14 6.85 ± 1.33 1.44** (1.12-1.86) -
Triglyceride (mmol/L) 1.24 ± 0.75 1.15 ± 0.56 1.69 ± 1.25 1.51*** (1.29-1.76) 1.46*** (1.22-1.75)
LDL-C (mmol/L) 2.89 ± 0.82 2.85 ± 0.80 3.07 ± 0.93 - -
HDL-C (mmol/L) 1.77 ± 0.48 1.77 ± 0.44 1.74 ± 0.62 - -
ApoB/ApoA 0.57 ± 0.18 0.56 ± 0.17 0.64 ± 0.23 1.45** (1.14-1.83) -
Lp(a) (mg/dL) 21.4 ± 21.7 21.9 ± 22.0 18.4 ± 19.8 - -
EU SCORE 2.60 ± 2.58 2.16 ± 2.12 4.73 ± 3.45 1.79*** (1.51-2.13) Not Incl.
Framingham Score 14.75 ± 3.54 14.21 ± 3.46 17.31 ± 2.74 2.63*** (1.87-3.71) Not Incl.
Characteristics of the study population stratified into survivors and deceased (all-cause). The last column contains HR for a sequentially stripped model including
all metabolic/physical markers (* p < 0.05, ** p < 0.01, *** p < 0.001).
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tive association to death whereas Area% was substituted
by Thickness% and Length% in the CVD and the CVD/
Cancer groups respectively, both with a negative associa-
tion to death (CVD HR per SD = 2.99 (1.84-4.87), p <
0.001, CVD/Cancer HR per SD = 2.04 (1.52-2.74), p <
0.001). The AC24 lost significant predictability when
combined with the other markers and was eliminated in
all combinations of patient groups and combinations
with metabolic/physical markers. Simulated area was
eliminated last or close to last in all elimination models.
The composite marker MACD showed highest
Table 2 Stratification of abdominal aortic calcification marker values according to cause of death shown as mean ±
standard deviation
All (n = 308) Survivors (n = 256) CVD (n = 20) Cancer (n = 27) CVD/Can (n = 47) Other (n = 5) All-cause (n = 52)
AC24 1.67 ± 2.55 1.35 ± 2.34 3.50 ± 2.35 3.41 ± 3.23 3.45 ± 2.86 1.35 ± 2.36 3.23 ± 2.86
Area (%) 0.6 ± 1.2 0.5 ± 1.1 1.0 ± 0.9 1.6 ± 1.8 1.3 ± 1.5 0.5 ± 1.1 1.2 ± 1.5
Sim. Area (%) 11 ± 17 8.9 ± 15.7 24 ± 16 25 ± 24 25 ± 21 8.7 ± 15.5 23 ± 21
Thickness (%) 11 ± 20 9.0 ± l9 17 ± 16 25 ± 28 21 ± 24 8.7 ± 19 20 ± 24
Wall (%) 1.03 ± 1.83 0.79 ± 1.64 2.08 ± 1.70 2.51 ± 2.68 2.33 ± 2.30 0.80 ± 1.63 2.16 ± 2.27
Length (%) 7.5 ± 12.8 6.0 ± 11.7 15.4 ± 11.2 17.3 ± 17.6 16.5 ± 15.1 5.9 ± 11.6 15.4 ± 15.0
NCD 3.8 ± 7.7 2.6 ± 6.4 8.5 ± 6.5 11.6 ± 13.4 10.3 ± 11.0 2.6 ± 6.3 9.6 ± 10.8
MAD factor 1.50 ± 1.66 1.29 ± 1.61 3.10 ± 1.23 2.30 ± 1.46 2.64 ± 1.41 1.29 ± 1.62 2.55 ± 1.52
MACD index 2.19 ± 2.44 1.80 ± 2.26 4.83 ± 1.90 3.91 ± 2.51 4.30 ± 2.29 1.81 ± 1.27 4.10 ± 2.43
Table 3 Hazard ratio per SD increase in marker value stratified into death cause and adjusted for physical/metabolic
markers, EU SCORE, and Framingham score respectively
Adjusted by HR/SD - HR/SD Physical/metabolic HR/SD EU SCORE HR/SD Framingham
AC24
CVD 1.66 (1.25-2.19)*** NS 1.38 (1.02-1.86)* NS
CVD/cancer 1.64 (1.35-2.00)*** 1.31 (1.06-1.63)* 1.40 (1.13-1.72)** 1.29 (1.02-1.63)*
Area
CVD 1.60 (1.16-2.20)** NS NS NS
CVD/cancer 1.68 (1.36-2.09)*** 1.32 (1.04-1.66)* 1.47 (1.16-1.86)** 1.34 (1.04-1.72)*
Sim. Area
CVD 2.96 (1.76-4.99)*** 2.00 (1.15-3.49)* 2.46 (1.41-4.27)** 2.27 (1.26-4.09)**
CVD/cancer 2.37 (1.73-3.25)*** 1.68 (1.20-2.34)** 1.96 (1.40-2.73)*** 1.79 (1.26-2.54)**
Thickness%
CVD NS NS NS NS
CVD/cancer 1.45(1.20-1.75)*** NS 1.27 (1.04-1.55)* NS
Wall %
CVD 1.50 (1.16-1.95)** NS NS NS
CVD/cancer 1.60 (1.34-1.91)*** 1.26 (1.04-1.53)* 1.42 (1.17-1.73)*** 1.30 (1.05-1.62)*
Length%
CVD 1.55 (1.18-2.04)** NS NS NS
CVD/cancer 1.61 (1.34-1.95)*** 1.26 (1.03-1.55)* 1.42 (1.16-1.73)*** 1.29 (1.03-1.62)*
NCD
CVD 2.44 (1.72-3.48)*** 1.76 (1.20-2.60)** 2.20 (1.48-3.26)*** 2.04 (1.34-3.12)***
CVD/cancer 2.28(1.79-2.90)*** 1.69 (1.30-2.21)*** 2.00 (1.53-2.62)*** 1.86 (1.40-2.47)***
MAD factor
CVD 3.37 (1.83-6.21)*** 2.44 (1.22-4.89)* 3.02 (1.55-5.86)** 2.85 (1.44-5.64)**
CVD/cancer 2.19 (1.58-3.04)*** 1.58 (1.11-2.26)* 1.83 (1.29-2.59)*** 1.74 (1.22-2.48)**
MACD index
CVD 5.22 (2.40-11.36)*** 3.17 (1.48-6.78)** 4.36 (1.97-9.66)*** 4.22 (1.79-9.97)***
CVD/cancer 2.99 (2.05-4.35)*** 2.01 (1.37-2.95)*** 2.43 (1.64-3.59)*** 2.27 (1.51-3.41)***
(* p < 0.05, ** p < 0.01, *** p < 0.001)
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(but not significantly so) than the combined elimination
models of the elementary calcification markers.
Predictive power in the high-risk group
In the CVD deaths group, the highest 10% of NCD or
MACD scores were significantly associated with death.
This did not hold forAC24 or Area% values in the same
group (Table 4). This relation persisted but with decreasing
hazard ratios when adjusted by standard composite meta-
bolic/physical markers (EU SCORE or Framingham score)
or the combined metabolic/physical parameter in the elim-
ination model from Table 1. Similar results were obtained
in the CVD/cancer group with slightly lower hazard ratios
and higher significance levels due to the larger population.
Comparing odds ratios (OR), the NCD exhibited a sig-
nificantly higher OR than the AC24 score (p = 0.04).
The OR for the MACD index was significantly higher
than for any other marker (compared with EU SCORE,
Framingham score and NCD, p < 0.05; compared with
all others, p < 0.001) (Figure 4).
Identification of patients at risk
Several markers significantly separated CVD deaths from
survivors prognostically based on the area under the
ROC-curve (AUC) (MACD 0.85 ± 0.06, SCORE 0.80 ±
0.06, Framingham 0.73 ± 0.07, triglyceride 0.74 ± 0.08,
total cholesterol 0.77 ± 0.06) or AAC-markers (AC24
0.79 ± 0.06, Area% 0.76 ± 0.06, NCD 0.82 ± 0.07). Com-
paring MACD AUC to the remaining markers, DeLong’s
test of significantly higher AUC yielded: SCORE p =
0.50, Framingham p = 0.12, triglycerides p = 0.24, total
cholesterol p = 0.16, AC24 p = 0.03, Area% p = 0.009
and NCD p = 0.14.
Combination of the MACD index with metabolic and
physical markers resulted in an AUC of up to 0.89 ±
Table 4 Hazard ratio for high risk subjects based on 90% threshold in the CVD deaths group
AC marker Adjusted by Hazard ratio alone AC24 Area% NCD MACD index
None - NS NS 10.9 (4.4-27)*** 15.6 (6.3-38)***
EU SCORE 4.9 (1.9-13)** NS NS 8.5 (3.2-23)*** 13.2 (4.9-35)***
Framingham NS NS NS 10.8 (4.1-28)*** 15.7 (6.1-40)***
All metabolic/physical 10.1 (4.1-25)*** NS NS 7.2 (2.8-18)*** 9.8 (3.7-26)***
(* p < 0.05, ** p < 0.01, *** p < 0.001).
Figure 4 Odds ratio of death in the CVD and cancer group who were assessed as being in the 10% at greatest risk of mortality,
versus survival in the remaining subjects. Significance of difference is indicated as * for p < 0.05, ** for p < 0.01, *** for p < 0.001 using the
likelihood ratio of appropriately combined logistic regression models.
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This combination provided the largest improvement
over MACD in the low risk range and was higher than
any of the other scores and significantly so (p < 0.05)
except for the SCORE (p = 0.11) and NCD (p = 0.07).
Discussion
We investigated whether more information could be
obtained from calcified deposits in the abdominal aorta
to better predict CVD death than the gold standard
AC24, which was developed from the Framingham
Heart Study cohorts. We hypothesised that the presence
of many small, spatially distributed, radiographically visi-
ble calcified deposits of varying shape in the lumbar
aorta had a stronger relation to CVD death than the
AC24 segment-wise scoring of the extent of calcified
deposits on the aortic wall.
The AC24 score [28] quantifies the burden of calcified
p l a q u e si nt h ea o r t ab ys e g m e n t - w i s es c o r i n go ft h e
extent of calcified deposit coverage of the aortic wall.
We investigated whether additional aspects of the out-
line of the individual plaques may be associated with the
progression and/or prognosis of atherosclerosis. We
analyzed the area, thickness, wall and length % of the
abdominal aorta covered by calcification and the num-
ber of distinct calcified deposits. Furthermore, we calcu-
lated the simulated plaque area in which the
atherosclerotic plaque size was estimated from the area
and form of the observed calcified lesion. Lastly, two
composite markers were created: i) The Morphological
Atherosclerotic Distribution (MAD) factor was con-
structed by dividing the simulated plaque area with the
absolute plaque area. ii) The Morphological Athero-
sclerotic Calcification Distribution (MACD) index given
by the NCD multiplied by the MAD factor.
In the present cohort, eight different markers (AC24,
area, simulated area, wall%, length%, NCD, MAD and
MACD) exhibited a significant hazard ratio per standard
deviation increase for death in the combined CVD/can-
cer group when adjusted for physical/metabolic markers,
the EU SCORE, and the Framingham score respectively.
However, only four markers (simulated area, NCD,
MAD and MACD) had sufficient power in risk segrega-
tion of CVD mortality when adjusted by physical/meta-
bolic markers, the EU SCORE and the Framingham
score. The composite MAD factor showed increased
sensitivity to CVD compared to cancer mortality. The
reason for this may be that the MAD factor essentially
scores how small and widely distributed the individual
calcified plaques appear. When the MAD factor was
combined with the number of calcified plaques, which
as an individual parameter alone was shown to be a
strong predictor of mortality, the resulting MACD index
displayed superior predictive power over any other
marker. The MACD index produced hazard ratios >4
per standard deviation increase, even after adjustment
for metabolic/physical factors. This is, to our knowledge,
the strongest predictor yet of mortality based on simple
x-rays.
In trying to identify which tool would be most useful
in clinical practice to identify CVD patients at highest
risk of death, we found, from applying the various scor-
ing systems to postmenopausal subjects who had died
from CVD, that the MACD index is potentially a better
predictor of mortality. The MACD index produced a
hazard ratio for death of more than 10, while the
hazards ratios for the AC24 and the Framingham score
were both insignificant, and the EU SCORE, had a value
of the hazard ratio of 5. Based on our study, postmeno-
pausal women identified by the MACD index as being
among the 10% at greatest risk of mortality from CVD,
would have a two-third probability of dying within the
following 8.5 years.
Conclusion
Atherosclerosis is a systemic disease in which lumbar
aortic calcifications occur (5). Recently, increasing atten-
tion has been devoted to the correlation between the
number of lumbar aortic calcifications in radiographs
and coronary calcifications [29] quantified by more
advanced and invasive imaging techniques such as elec-
tron beam tomography (EBT) for coronary artery cal-
cium scoring (CACS). The publications suggest
radiographs provide equally valuable information on
CVD and offer the advantage of simplicity for in-office
quantification [30-33]. Some studies even suggest the
number of lumbar aortic calcifications is an independent
predictor of CVD events [34]. Importantly, only the cal-
cified core of an atherosclerotic lesion is detected in x-
rays whereas the surrounding necrotic tissue and region
of high remodelling and fibrosis are not detectable.
Hence, the actual pathologically involved area is under-
estimated in radiographs. Consequently, the morpholo-
gical enlargement of plaques (used in the MAD factor
and thereby the MACD index) may carry information
related to the projected area of the inflammatory pro-
cesses and indirectly indicate an increased risk. This
additional information may result in a better prediction
of mortality risk than the current state-of-the-art, the
AC24 radiographic scoring of atherosclerotic plaques.
The present study has its limitations. Its findings are
only valid for a follow-up period of 8.5 years and may
not necessarily apply to shorter follow-ups. For short
follow-up times, the predictive power could possibly be
based only on the total plaque burden as described by
the AC24 score. Furthermore, the present population is
restricted in size, geographical and ethnic content to
postmenopausal Danish women. The present study
Nielsen et al. BMC Cardiovascular Disorders 2010, 10:56
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Page 8 of 10needs validation in other populations and longer term
clinical settings.
In conclusion, assessment of the shape, size, number,
distribution, and extent of lumbar aortic calcifications
may aid in identifying patients at risk of CVD death and
thus most in need of treatment.
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